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doi:10.1016/j.ejvs.2009.05.010Abstract Objectives: To compare carotid endarterectomy with carotid artery stenting in the
prevention of stroke in patients with asymptomatic carotid stenosis.
Design: A large, simple, pragmatic international trial of at least 5000 patients with asymptom-
atic carotid stenosis in whom intervention is thought to be needed but where there is substan-
tial uncertainty about the appropriate choice of treatment. The trial is designed to fit in easily
with normal clinical practice.
Materials & Methods: A short (w2 min) telephone call is made to randomise patients to either
carotid endarterectomy (CEA) or stenting (CAS). Follow-up by the collaborator will be at one
month after the procedure (simple 1-page form) and by the ACST office for 5-years post-proce-
dure. Data will be analysed on an intention-to-treat basis; main outcomes will be 30-day
myocardial infarction, stroke and death, and 5-year stroke rates. In addition, appropriate
subgroup analyses will be undertaken, and health economic evaluation will consider proce-
dural and stroke-related healthcare costs and quality of life.
Conclusion: Collaborators who routinely undertake CEA and CAS are encouraged to participate
in ACST-2. This trial, now funded and open for randomisation, will provide important evidence
comparing the immediate and long-term safety and efficacy of carotid endarterectomy and
stenting in patients with asymptomatic carotid stenosis.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.8725 3746; fax: þ44 20 8725 3782.
.com (A. Halliday).
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240 N. Rudarakanchana et al.Patients with significant carotid artery stenosis (60e99%)
are 3 times more likely to suffer disabling or fatal ischaemic
stroke when compared with the general population.1
Approximately 100,000 people in the UK and at least one
million people in Europe have severe carotid stenosis.2,3
Trials in symptomatic patients support use of CEA to
prevent stroke, but there is currently no robust evidence
that allows us to predict which asymptomatic lesions will
cause a stroke; therefore, for some patients with tight
asymptomatic carotid artery stenosis intervention may be
indicated.4,5
Carotid stenosis may be treated surgically by open
removal of plaque through carotid endarterectomy (CEA)
or by endovascular means, using carotid stenting (CAS);
these procedures may actually cause stroke if thrombosis
occurs in the endarterectomised vessel or if emboli are
dislodged from the carotid plaque and block the distal
cerebral circulation. The long-term outcome balancing
peri-operative risk and stroke prevention benefit for both
procedures needs careful examination and good medical
treatment is essential to minimise stroke risk from other
factors.6,7,8
The use of prophylactic carotid endarterectomy in
patients with asymptomatic carotid stenosis has caused
considerable controversy. The prevalence of carotid
stenosis >50% is 5e10% in the older population, and their
annual stroke risk in screening studies has been estimated
as 1e3%. However, even with this lower risk, because most
strokes arise in patients without previous symptoms, the
potential benefit of intervention in the form of CEA in
asymptomatic patients may be important. A number of
randomised trials have been conducted recently comparing
stroke rates in asymptomatic patients. The first Asymp-
tomatic Carotid Surgery Trial (ACST-19) and the Asymp-
tomatic Carotid Atherosclerosis Study (ACAS10) enrolled
almost 5000 patients with carotid stenosis and no stroke or
stroke-like symptoms in the preceding 6 months. In ACST-1,
which reported 5-year results in 2004, 3120 patients were
randomised between immediate CEA and medical therapy,
and delayed CEA (waiting until operation more clearly
needed, for example, if symptoms occurred) and medical
therapy. Results showed that even though immediate CEA
involved a small (w3%) but definite peri-procedural risk of
stroke or death, there was a significant (w3% versusw12%,
p< 0.001) reduction in the subsequent stroke rate over the
next 5-years and a net gain (w6% versus w12%) in the
overall 5-year risk of stroke or peri-procedural death.9 In
1995, for a smaller group, ACAS had shown similar results
and CEA reduced the overall 5-year risk of ipsilateral stroke
and death from 11% to 5.1% (pZ 0.004).10 These results
provided robust and contemporary evidence that CEA
prevents stroke in patients with asymptomatic carotid
stenosis.
Recent data arising from the SPARCL trial indicates that
the increased use of statins does reduce stroke risk in
patients with asymptomatic carotid disease (although their
degree of stenosis was undefined).11 From ACST we know
that CEA in patients up to 75 years also significantly reduces
stroke risk. When intervention for these asymptomatic
patients is indicated. CEA is a well proven procedure but
less invasive endovascular stenting is now an attractive
alternative.Endovascular treatment for carotid stenosis is commonly
performed under local anaesthetic using remote percuta-
neous arterial access. Compared to CEA, CAS can be used to
reach surgically inaccessible lesions, avoids a surgical
wound, reduces the risk of cranial nerve injury, is usually
done with shorter hospital stay and might reduce the risk of
peri-procedural myocardial infarction or stroke. However,
there are complications associated with stenting: injury to
the access vessels from introduction of wires and catheters
may result in vessel dissection; crossing of the atheroscle-
rotic lesion to place the stent may cause distal embolisation
and stroke, even though fine umbrella-like cerebral
protection devices have been developed to provide
protection. Radiological contrast can precipitate allergic
reactions and is nephrotoxic, particularly in patients with
previously compromised renal function. CAS is already in
wide use: for example, approximately 7000 carotid stents
per year are inserted in Germany and worldwide most
stents are used in patients with asymptomatic carotid
disease. There remains, however, substantial uncertainty
concerning the immediate hazards and long-term reliability
of CAS, with recent studies highlighting a possible increased
incidence of 30-day adverse events in octogenarians and in
those with unfavourable plaque morphology.12
A recent systematic review and meta-analysis of ten
mainly symptomatic trials of CEA versus CAS concluded that
both procedures were equivalent in terms of death and
nonfatal myocardial infarction. The pooled data was not
sufficient to determine the differential impact on stroke
rates, though results suggested a trend towards an increase
in stroke risk following CAS.13,14
No large trial has specifically set out to compare CAS and
CEA in asymptomatic patients, although four published
trials of CEA versus CAS and the lead-in phase of the Carotid
Revascularisation Endarterectomy versus Stent Trial
(CREST) have included some asymptomatic patients15e19
(see Table 1). In randomised trials patient populations were
mostly symptomatic and none reported separate subgroup
analysis for asymptomatic patients. A pooled subgroup
analysis of asymptomatic patients from these trials did not
provide meaningful conclusions because of small numbers
of patients and wide confidence intervals.13 The only trial
involving solely asymptomatic patients was small (NZ 85)
and reported no major complications (stroke or death) in
either CEA or CAS treated groups.18 Because of the lack of
randomised trial evidence, a 2008 review of guidelines by
the European Stroke Initiative recommends that CAS in
patients with asymptomatic carotid stenosis should only be
undertaken in randomised controlled trials.
Because stroke risk (for CEA and for CAS) is lower for
asymptomatic patients, a large international multi-centred
trial is required to compare immediate (30-day) procedural
risk and long-term stroke risk reduction in patients with
asymptomatic carotid stenosis. ACST-2 aims to compare
CEA with CAS in asymptomatic patients and provide clinicians
with robust evidence as to which (if either) intervention is
least hazardous and which can provide best long-term
stroke reduction benefit. The trial is designed to fit in easily
with everyday clinical practice. The trial protocol is
summarised in Appendix I. We invite all clinicians who
practice CEA and/or CAS to consider joining ACST-2, by
contacting us through our website (www.acst.org.uk),
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Asymptomatic Carotid Surgery Trial-2 241email (acst@sgul.ac.uk), phone (þ44 208 725 3746), fax
(þ44 208 725 3782), or by writing to us at ACST-2, Depart-
ment of Cardiac and Vascular Sciences, St George’s
University of London, Cranmer Terrace, London SW17 0RE.
Funding
The ACST-2 trial is funded by the UK National Institute of
Health Research (NIHR) Health Technology Assessment
programme and by the BUPA Foundation. The trial sponsor
is the University of Oxford.Appendix I
Design and Objectives of ACST-2
The ACST-2 trial is a large, international randomised trial
comparing CEA versus CAS in patients with asymptomatic
carotid stenosis. Patients are suitable if prompt physical
intervention is thought to be needed, but where (after
suitable angiography has shown both procedures to be
possible) there is still substantial uncertainty shared by
patient and doctor about whether CEA or CAS is the more
appropriate choice. Half will be randomised to CEA and half
to CAS. All patients will be followed up for 5 years and
analyses will be on an intention-to-treat basis. Basing
eligibility on uncertainty should ensure large-scale
recruitment of an appropriately heterogeneous group,
thereby increasing the applicability of the study, and
enabling determination of the effects of patient charac-
teristics or of the devices used.
Each centre will have a collaborating neurologist (or
stroke physician), vascular surgeon and stenting inter-
ventionalist, responsible for patient recruitment, treat-
ment and follow-up. The stenting interventionalist may be
a radiologist, cardiologist, surgeon or physician with
specialist training in carotid stenting. A ‘centre’ may be
organised between colleagues in neighbouring hospitals but
the neurological assessments will be carried out by
a participating neurologist or stroke physician. Each
collaborator must send a ‘Track Record’ of their previous
experience with CEA or CAS before starting the trial,
countersigned by the local collaborating stroke physician or
neurologist. These records will be anonymised and then
reviewed by the technical management committee.
Doctors must have performed 25 or more of the particular
procedure in order to participate in the trial, but their
overall experience will be taken into account. In general
collaborators should have 8% stroke and death risk for
symptomatic patients and 4% stroke and death risk for
asymptomatic patients, or some appropriate combination
of these percentages.
Ethical approval is required for each centre and the
ACST office is happy to assist prospective collaborators with
the process of obtaining this. Additionally, a ‘Memorandum
of Intent’ must be signed by each centre, and is counter-
signed by the University of Oxford. Once this is done,
ethical approval obtained and Track Records approved
centrally, eligible patients can be enrolled.
The trial is designed to maximize recruitment by mini-
mising each collaborator’s workload and it can be
242 N. Rudarakanchana et al.integrated easily into routine healthcare. Annual follow-up
will then be organised by the ACST office and the random-
isation form and 1-month post-procedural form are the only
forms that routinely need completion by the doctor.
The primary objectives of the trial are to compare 1)
peri-procedural risks (MI, stroke and death within the first
month after the allocated CEA or CAS is attempted), and 2)
long-term (up to 5 or more years) prevention of stroke,
particularly disabling or fatal stroke in the two treatment
groups. The secondary aims are health economic evaluation
for procedural costs, stroke-related healthcare costs and
quality of life assessment. Further subgroup analyses may
identify patient groups in which one or other procedure is
clearly preferable.
The complete trial protocol may be downloaded from:
www.acst.org.uk.References
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